Skip to main content

The Essential

A BDC Watchlist Finds $5.7 Billion in Portfolio Loans ‘At-Risk’

The fair value of these loans declined by 17 percent during the first quarter, according to 9fin.

Hedgies Eye Three Biopharma IPOs

A number of prominent hedge funds hope to duplicate the success of the most recent biopharma offerings.

Sponsored

Stagflation: Risks and Opportunities in Global Equities

Churchill’s Ken Kencel on Private Credit’s Second Act

From the myth of “semi-liquid” private credit to why the highest returns can be misleading, Kencel challenges some of the industry’s most widely held assumptions.

Related Content

Private Credit’s Rapid Growth Through BDCs Could Erode Quality, Returns

James Comtois

It’s Not Business as Usual for BDCs

Jonathan Kandell

Job Board – For Investors Only

Investment Analyst

​

University of Virginia

​
Learn More

Investment Analyst

​

DUMAC Inc

​
Learn More

Investment Analyst

​

DUMAC Inc

​
Learn More

Investment Analyst

​

BlueCross BlueShield Association

​
Learn More

1270 Avenue of the Americas, Suite 1120

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site.

 

| Unsubscribe

LinkedIn
X
Bluesky
Instagram